JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $7
Lake Street Remains a Buy on Aquestive Therapeutics (AQST)
Leerink Partners Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $12
Aquestive Therapeutics: A Buy Rating on Revolutionary Allergy Treatments and Strategic Pipeline Expansion
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $7
Aquestive Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Aquestive Therapeutics Analyst Ratings
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $10
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Aquestive Therapeutics: A Buy Rating on Underappreciated Market Potential and Innovative Pipeline
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $9 Price Target
Aquestive Therapeutics Analyst Ratings
Buy Rating Affirmed for Aquestive Therapeutics as Anaphylm Poised to Transform Epinephrine Market
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Aquestive Therapeutics Analyst Ratings
JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Aquestive Therapeutics (AQST)